Last reviewed · How we verify
Eganelisib in combination with cytarabine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Eganelisib in combination with cytarabine (Eganelisib in combination with cytarabine) — Stelexis BioSciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Eganelisib in combination with cytarabine TARGET | Eganelisib in combination with cytarabine | Stelexis BioSciences | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Eganelisib in combination with cytarabine CI watch — RSS
- Eganelisib in combination with cytarabine CI watch — Atom
- Eganelisib in combination with cytarabine CI watch — JSON
- Eganelisib in combination with cytarabine alone — RSS
Cite this brief
Drug Landscape (2026). Eganelisib in combination with cytarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/eganelisib-in-combination-with-cytarabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab